In this quarterly report, we look at a few of the companies beginning to make their marks on the US generics market either with their fi nished dose products or active ingredients, and analyze trends and statistics relating to the market as a whole.
In this quarterly report, we look at a few of the companies beginning to make their marks on the US generics market either with their fi nished dose products or active ingredients, and analyze trends and statistics relating to the market as a whole.
Oncology Intelligence 2014 Report (Second Updated Edition)
Report to Cover all Aspects of Cancer Drug Development Intelligence
COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING
Oncology Drug Report 2014 –World’s Largest Active Resource for Decision Making, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.
For Details Visit :- https://omicsx.com/reports/cancer/oncology-intelligence-report-2014/
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...IMARC Group
The global orphan drugs market exhibited moderate growth during 2014-2019. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years.
To learn more about this market, visit us at: https://www.imarcgroup.com/orphan-drugs-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The report provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. The competitive landscape of the market has also been analyzed in the report with the detailed profiles of the key players.
For more information, request for a free sample report here: https://www.imarcgroup.com/orphan-drugs-market/requestsample
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
In this quarterly report, we look at a few of the companies beginning to make their marks on the US generics market either with their fi nished dose products or active ingredients, and analyze trends and statistics relating to the market as a whole.
Oncology Intelligence 2014 Report (Second Updated Edition)
Report to Cover all Aspects of Cancer Drug Development Intelligence
COMPANIES * MOLECULES * INDICATIONS * TECHNOLOGIES * DEALS * FUNDING
Oncology Drug Report 2014 –World’s Largest Active Resource for Decision Making, is designed to curtail down the efforts in identifying the real picture of present cancer drug development market, by bringing more authentic data under review and eliminating the undesired information.
For Details Visit :- https://omicsx.com/reports/cancer/oncology-intelligence-report-2014/
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...IMARC Group
The global orphan drugs market exhibited moderate growth during 2014-2019. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years.
To learn more about this market, visit us at: https://www.imarcgroup.com/orphan-drugs-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The report provides an analysis of the key trends in each sub-segment of the global orphan drugs market report, along with forecasts for growth at the global, regional and country level from 2020-2025. The competitive landscape of the market has also been analyzed in the report with the detailed profiles of the key players.
For more information, request for a free sample report here: https://www.imarcgroup.com/orphan-drugs-market/requestsample
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
This presentation shows how's the competitive dynamic of Brazilian market, the real growth of the same and opportunities that usually are not shown in ordinary presentations. There are also mentioned the Critical Success Factors to enter in the market and not be surprised.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
The Nashville Health Care Council is an association of healthcare industry leaders working together to further establish Nashville's position as the nation's healthcare industry capital.
This presentation shows how's the competitive dynamic of Brazilian market, the real growth of the same and opportunities that usually are not shown in ordinary presentations. There are also mentioned the Critical Success Factors to enter in the market and not be surprised.
Global antibody drug conjugate market & pipeline insight2020KuicK Research
" Global Antibody Drug Conjugate Market & Pipeline Insight 2020" Report Highlight:
Global Antibody Drug Conjugates Market Overview
Mechanism of Antibody Drug Conjugates
Global Antibody Drug Conjugates Clinical Pipeline by Company, Indication & Phase
Global Antibody Drug Conjugates Clinical Pipeline: 148 ADC
Marketed Antibody Drug Conjugates Clinical Insight: 8 ADC
Antibody Drug Conjugates Patent Analysis
Global Antibody Drug Conjugates Market Future Prospects
The Nashville Health Care Council is an association of healthcare industry leaders working together to further establish Nashville's position as the nation's healthcare industry capital.
Tesla Revolution 2016 - Come ricaricare un’auto elettrica a casa, in azienda ...Tesla Club Italy
Sergio Torre / Responsabile Pianificazione Strategica & Controlling di Duferco Energia
Ricaricare la tua auto elettrica è molto più facile di quanto si possa pensare. Puoi farlo direttamente a casa tua, in azienda o in viaggio, con modalità molto semplici e davvero vantaggiose sfruttando una rete di ricarica già presente su tutto il territorio italiano e in rapida crescita. Sono questi i punti su cui si focalizza l’attività di Duferco Energia, attraverso il brand DUE Energie, nell’ambito della Green Mobility. Presente in 64 città italiane con oltre 500 colonnine di ricarica, Duferco Energia è, infatti, in grado di fornire interessanti strumenti per la ricarica dei veicoli elettrici con servizi dedicati sia alla ricarica domestica sia in azienda. Opportunità, vantaggi e strumenti innovativi studiati appositamente per i green movers con prodotti dedicati ai clienti Tesla e a tutti i possessori di veicoli elettrici e ibridi plug-in.
We are very honored to be able to invite the Senior Managing Director of FTI Consulting (FCN US, MV $1.5bn), a billion-dollar NYSE-listed global forensic consulting firm, as a guest speaker in our SMU classes to share his knowledge and wisdom with the students in the Accounting Fraud in Asia course in Week 6, the week of 9th February. Over the years in the Asian capital jungles, the FTI people are amongst the few professionals whom I respect for their on-the-field expertise and thought leadership in the area of fraud and forensic investigation. I am sure that the talk will definitely make an impact for our SMU students who will learn not only invaluable lessons from the speaker’s knowledge and wisdom but also about FTI Consulting as their future career choice.
In this quarterly report, we look at a few of the companies beginning to make their marks on the US generics market either with their fi nished dose products or active ingredients, and analyze trends and statistics relating to the market as a whole.
The global organ-on-a-chip market generated revenue of US$ 23.3 million in 2020 and is expected to reach US$ 116.7 million by 2025 with a CAGR of 38.0% in the forecast period. The organ-on-a-chip market report offers a comprehensive market analysis of the different segments and regions that lets readers make crucial business-related decisions with a wealth of information enclosed in this report. The research report offers both qualitative and quantitative information on the global organ-on-a-chip market. In qualitative terms, the organ-on-a-chip market report provides insights into numerous factors, such as market determinants, value chain analysis, emerging trends, growth opportunity analysis, porters five-force model analysis and macro-economic factors, segment analysis, regional analysis at a granular level. Similarly, in quantitative terms, the report provides historical and forecast market numbers of organ-on-a-chip in various segments such as by Offerings, type, application & end-user at global, regional, and country-level. Also, the report provides a detailed analysis of the market vendors and their product offerings. The report also covers details of the competitive market environment and includes information on the capabilities and competencies of market vendors.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
R&D leadership in crisis: rebuilding innovation through peopleRung Jaismut
We are delighted to announce the publication of Heidrick & Struggles’ R&D leadership in crisis: rebuilding innovation through people.
In this research paper, we explore the thoughts and opinions of 150 senior R&D executives across a range of global pharmaceutical companies. We found that these executives are inundated with multiple tasks and are unable to focus on creating productive innovation cultures. A key reason for R&D project failure, above and beyond safety and efficacy, was weak alignment between R&D and commercial organizations. Startlingly, 60% of executives surveyed stated that they would be interested in considering career options outside of R&D.
We believe that difficult questions must be addressed around the current R&D leadership structures in place, as well as the profile of the next generation of leaders needed to successfully drive the required change.
We hope you find the report to be both thoughtful and provocative. We would be very interested in hearing your perspectives on the issues raised and discussing your thoughts on potential solutions
The National Association of Pharmaceutical Manufacturers (NAPM) was established in 1977 as A Section 21 Trade Association which. It is a voluntary, non-profit organisation consisting of South African and Generics based Pharmaceutical manufacturers and distributors. The NAPM has a diverse membership comprising of 18 companies. Part of the NAPM’s function is to ensure that the sector plays a constructive role in our country’s economic growth, development and transformation and thereby create an environment in which the sector can thrive, expand, be competitive and enhance access of medicines to all of our country’s citizens.
Spotlight On... Anti-Thrombotics, A Review of Jan-Mar 2011-- Pharma Matters R...Thomson Reuters
The thrombosis market is poised to change dramatically. The possibility of engineering a replacement for warfarin, or a side-effect free oral anticoagulant suitable for chronic thrombosis prevention has presented an attractive opportunity for the pharma industry, and a raft of new products are now entering the market.
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
1. Image CopyrIght: iSTOCKpHOTO
MOVERS AND SHAKERS
A PHARMA MATTERS REPORT.
April-June 2010
The Thomson Reuters quarterly report on the US generics
industry using strategic intelligence and competitive analysis
information from Newport Premium™, the critical product
targeting and global business development system from
the industry authority on the global generics market.
2. In this quarterly report, we look at a few of the companies
beginning to make their marks on the US generics market either
with their finished dose products or active ingredients, and
analyze trends and statistics relating to the market as a whole.
For more information on Thomson Reuters
API Intelligence solutions, including Newport Premium,
visit go.thomsonreuters.com/newport
PHARMA MATTERS | MOVERS AND SHAKERS
3. SeCTiOn i: inTrODuCTiOn WHAT iS
An AnDA?
The European Generic Association had its annual meeting in Rome
in June 2010. Attendees concluded that conditions look positive An Abbreviated New
Drug Application
for the US generic market while the European generic industry
(ANDA) is the first
continues to struggle with delays to generic launches, disincentives step for a generic
for generic prescribing in a number of countries, increasing pricing drug in the US. It
pressures, and government-mandated price cuts. is submitted to the
FDA to prove that
Why does the situation look better in the US? First, a large the generic version
number of products will lose patent protection over the next few is bioequivalent to
years. Second, the pricing environment in the US has stabilized. the innovator drug
Richard Silver from Barclays Capital explained that the relative in question. On
approval, the generic
pricing stability is the result of industry consolidation over the version is added
past 10 years and explained that the remaining competitors to the Approved
are more rational in their pricing strategies. Third, generic Drug Products List
penetration is occurring at ever-increasing rates. For example, (“Orange Book”) and
US generic substitution today occurs at 80 percent conversion the company may
manufacture and
over four to six weeks as compared to 60 percent within six to market it. An ANDA
eight months just a few years ago. Drivers accounting for the may be submitted
rapid substitution rate include drug retailers’ increased focus on before the patent on
aggressive generic substitution with higher profitability, the rise the innovator drug
of authorized generics, and therapeutic substitution. expires. However,
in that case, the
The future is not all rosy, however, for the US generic industry. ANDA must include a
Raymond De Vre from McKinsey and Company warned the certification indicating
that the filer does
audience that the good times generic companies have enjoyed
not seek to market
over the past decade will end soon. While the global generics the product before
market shows attractive growth with significant patent expiries the expiry of the
for small molecules occurring in 2011 and 2012, there will Orange Book-listed
be fewer small molecule opportunities after 2012. Although patents (“paragraph
III certification”) or
biologics present a large opportunity for generics beyond 2010,
that the filer believes
the manufacturing and regulatory hurdles are high and it that its product
remains to be seen how many companies can realistically invest does not infringe the
in these products for the long term. Orange Book-listed
patents or that the
Mr. Silver expected industry consolidation to continue. Orange Book-listed
However, he predicted that the majority of M&A activity will patents are invalid
be focused outside the US. Certainly, there was a significant (“paragraph IV
amount of M&A activity in the second quarter, and, as seen in certification”).
the Notable Deals section of this report, there were a number of WHAT Are “A”
deals focused on emerging markets. rATeD DrugS?
“A” rated drugs
are considered
therapeutically
equivalent and can
be substituted for
each other. “A” rated
drugs are designated
as AA, AB, AN, AO,
AP, and AT in the
Orange Book.
PHARMA MATTERS | MOVERS AND SHAKERS
4. WHAT iS A SeCTiOn ii: AnDA ApprOvAlS
uS Dmf?
TOTAl ‘A’-rATeD AnDAS by COunTry Of Origin Of
A DMF (Drug Master AppliCAnT fOr April TO June 2010
File) is a confidential
document 62
covering a specific
manufacturing
facility, process or 44
article used in the
manufacturing,
processing,
packaging or storing
of a bulk drug. A DMF
is reviewed by the
11 10
FDA only if an ANDA
6
or NDA referencing 3 3 2 1 1 1 1 1 1
that particular DMF
is filed. An ANDA
or NDA will not be
A
A
Y
ZE E L
SW D
EN
N
S
Y
D
AU N
CA A
DA
AN
AL
approved until any
AN
ND
US
DI
RI
AN
AN
PA
A
RA
ED
NA
IW
RD
ST
IT
IN
JA
RM
LA
RL
EL
IS
TA
issues with the DMF
JO
IC
ER
GE
TH
IT
are resolved.
SW
NE
WHAT iS THe 180- During the second quarter of 2010, US-based companies
DAy exCluSiviTy? received the most Abbreviated New Drug Applications (ANDA)
In order to encourage approvals, with 62 approvals going to 24 groups. During
generic companies the same period, 19 Indian companies received a total of 44
to develop non-
infringing products
approvals. The approval numbers were considerably higher than
and challenge invalid during the first quarter, when US-based companies received 23
patents, the Hatch- approvals and Indian companies received 22 approvals.
Waxman act provides
the incentive of
grOupS WiTH THe mOST ‘A’-rATeD AnDA ApprOvAlS
180 days of market fOr April TO June 2010
exclusivity for the first
18
company to file an
ANDA with paragraph
IV certification for a
product. The FDA
may not approve
additional ANDAs for 9 9
a period of 180 days
commencing from 6 6 6 6
the first commercial 5 5
4 4 4
marketing of the
first-to-file product.
In cases where more
than one ANDA
with Paragraph IV
nc
nc
td
nc
G
d
G
p
td
d
d
KG
ou
Lt
Lt
Lt
sA
sA
certification is filed
sL
sL
sI
sI
sI
im
Gr
b
n
a
ie
al
al
iu
rti
rie
rie
m
La
pi
he
or
tic
en
tic
va
y's
Lu
ar
st
st
co
on the same day, the
at
el
eu
eu
es
No
Ph
du
dd
du
Ar
ng
r
Fr
bo
ac
ac
In
In
Re
o
es
rI
m
m
nd
La
al
al
period of exclusivity
ge
rid
Dr
ar
ar
tic
bi
tic
n
rin
Ph
Ph
St
yla
ro
eu
eu
eh
Au
may be shared.
nt
n
M
ac
ac
so
Bo
ge
m
m
at
ar
ar
Sa
W
Ph
Ph
va
n
Su
Te
During the second quarter of 2010, Mylan (US) received 18 ANDA
approvals, putting the company on top of the list, followed by
Sagent (US) and Teva (Israel), each with 9 approvals.
PHARMA MATTERS | MOVERS AND SHAKERS
5. SeCTiOn iii: pArAgrApH iv CHAllengeS WHAT iS A
biOSimilAr
In the second quarter of 2010, we learned of the first Paragraph ACCOrDing
IV patent challenges on six new active ingredients or TO uS
combinations, down from 13 during the previous quarter. regulATiOnS?
grOupS WiTH THe mOST pATenT CHAllengeS On reCOrD A biosimilar
AS Of June 2010 product is defined
in the Act to mean
a biological product
152
that is both “highly
similar to the
reference product
notwithstanding
83 81 minor differences
62
in clinically inactive
60
components” and
43 41
35 34 for which “there
30 28 27 are no clinically
meaningful
differences between
the biological
product and the
Te
No
M
W
Ap
Su
Dr
Ac
Da
Lu
Pa
Im
yla
at
va
pi
ta
pa
rP
n
ot
iic
va
Re
so
n
Ph
vis
reference product in
n
ex
hi
Ph
xL
rti
ha
dd
Lt
n
La
ar
sA
Sa
In
Gr
ar
rm
ab
Ph
d
y's
bo
m
c
m
nk
ou
G
o
terms of the safety,
ac
ar
ac
Gr
ra
ra
ac
yo
p
m
e
eu
to
ou
to
eu
ut
Hf
ac
Co
rie
r
tic
ica
p
tic
purity, and potency
ie
eu
sI
Lt
al
sI
al
lC
tic
d
nc
nc
In
In
om
al
of the product.”
du
du
sI
pa
st
st
nc
rie
ni
rie
Interchangeability
es
sL
sL
In
td
td
c
is defined as a
biological product
that “may be
Teva continued to be by far the most prolific filer of ANDAs with substituted for the
patent challenges. At the time of writing this report, we were reference product
linking the company to challenges on 152 products, up from without the
149 products the quarter before. Novartis (Sandoz) and Mylan intervention of the
healthcare provider
were in second and third place, with links to 83 and 81 patent
who prescribed the
challenge products, respectively. reference product.”
PHARMA MATTERS | MOVERS AND SHAKERS
6. prODuCTS firST expOSeD TO pArAgrApH iv CHAllengeS, AS repOrTeD by
WHAT iS A
pArAgrApH iv THe fDA beTWeen April AnD June 2010
CHAllenge?
ACTive ingreDienT: • Perrigo has submitted an ANDA with Paragraph IV
Bioequivalent butoconazole nitrate certification for a generic version of Gynazole-1 (butoconazole
generic versions of
pOSTeD by fDA: nitrate) vaginal cream.
drugs that are not
June 8, 2010
protected by patents • The Orange Book lists two patents covering Gynazole-1
can be produced and brAnD nAme: vaginal cream.
marketed in the US by gynazole-1®
- US Patent 5,266,329 will expire on Nov. 30, 2010.
any company, subject
to FDA approval.
nDA HOlDer: - US Patent 5,993,856 will expire on Nov. 17, 2017.
Kv pharmaceutical
However, a generic
Company - KV has alleged that Perrigo infringes US Patent 5,993,856.
company may obtain
• At the time the first ANDA with Paragraph IV certification was
FDA approval before
patent expiry if it
submitted for a generic version of Gynazole-1 vaginal cream,
certifies its product Gedeon Richter, Mediolast, and Roche Palo Alto held DMFs
does not infringe for butoconazole nitrate.
the listed patents
or the patents are ACTive ingreDienT: • Apotex and Teva have submitted ANDAs with Paragraph
invalid (paragraph IV eletriptan IV certification for generic versions of Relpax (eletriptan
certification). Patent hydrobromide
hydrobromide) tablets.
holders may then sue
pOSTeD by fDA:
the ANDA filer for • The Orange Book lists two patents covering Relpax tablets.
June 8, 2010
patent infringement. If - US Patent 5,545,644 includes claims directed to the drug
the patent holder sues brAnD nAme:
the ANDA filer within relpax® substance, drug product, and the treatment of migraine
45 days of notification, with or without aura. It will expire on Dec. 26, 2016.
nDA HOlDer:
the FDA may not pfizer - US Patent 6,110,940 is directed to a crystalline form of
approve the ANDA for eletriptan hydrobromide. It will expire on Aug. 29, 2017.
30 months from the
date of notification. If - Pfizer has alleged that Apotex and Teva infringe US Patent
no suit is filed within 6,110,940. In its notification letter, Apotex asserted that its
45 days, the FDA may proposed product would not infringe the patent because
approve the ANDA at
it would contain an amorphous solid form of eletriptan
any time.
hydrobromide. Teva also indicated that its proposed
product would not contain the polymorphic form of
eletriptan hydrobromide claimed in US Patent 6,110,940.
• At the time the first ANDA was submitted for a generic
version of Relpax tablets, Teva and Apotex held DMFs for
eletriptan hydrobromide.
ACTive ingreDienT: • At least one company has submitted an ANDA with
eprosartan mesylate Paragraph IV certification for a generic version of Teveten
pOSTeD by fDA: (eprosartan mesylate) tablets. We do not know the filer’s
June 22, 2010 identity at this time.
brAnD nAme: • The Orange Book lists only one unexpired patent covering
Teveten®
Teveten tablets.
nDA HOlDer: US Patent 5,656,650 includes claims directed to the use of
Abbott
eprosartan stepwise or in physical combination with a diuretic for
the treatment of hypertension. It will expire on Aug. 12, 2014.
• At the time the first ANDA was submitted for a generic version
of Teveten tablets, Jubilant Organosys and Hetero Drugs held
the DMFs for eprosartan mesylate most likely to be referenced
in an ANDA.
PHARMA MATTERS | MOVERS AND SHAKERS
7. ACTive ingreDienT: • At least one company has filed an ANDA with Paragraph IV
ketoconazole certification for a generic version of Extina (ketoconazole)
pOSTeD by fDA: foam. We do not know the filer’s identity at this time.
may 18, 2010
• The Orange Book lists only US Patent 7,553,835 for Extina
brAnD nAme: foam. That patent includes claims to the drug product and its
extina®
use in the treatment of seborrhea dermatitis. It will expire on
nDA HOlDer: Oct. 19, 2018.
gSK
• At the time of the first ANDA submission for a generic version
of Extina foam, several companies held active DMFs for
ketoconazole. This is not surprising because other generic
ketoconazole products have been approved in the US for years.
ACTive ingreDienT: • Lupin has submitted an ANDA with Paragraph IV certification for a
ranolazine generic version of Ranexa (ranolazine) extended-release tablets.
pOSTeD by fDA: • The Orange Book lists 10 patents covering Ranexa extended-
June 8, 2010
release tablets, all expiring on May 27, 2019.
brAnD nAme:
Lupin’s ANDA for a generic version of Ranexa included
ranexa®
Paragraph IV certification to all 10 patents. Roche and Gilead
nDA HOlDer: have alleged infringement of nine of the patents.
gilead
• The FDA reported at least eight active DMFs for ranolazine
on file at the time the first ANDA was submitted for a generic
version of Ranexa extended-release tablets, including one
held by Lupin.
ACTive ingreDienT: • Mylan has filed an ANDA with Paragraph IV certification for a
sunitinib malate generic version of Sutent (sunitinib malate) capsules.
pOSTeD by fDA: • The Orange Book lists three patents covering Sutent capsules.
April 19, 2010
- US Patent 6,573,293 and US Patent 7,125,905 include both
brAnD nAme:
drug substance and drug product claims directed to Sutent
Sutent®
capsules. They will expire on Feb. 15, 2021.
nDA HOlDer:
pfizer - US Patent 7,211,600 claims the treatment of
gastrointestinal stromal tumors with sunitinib. It will expire
on Dec. 22, 2020.
- Pfizer has alleged that Mylan infringes all three listed
patents.
• At the time of the first ANDA submission for a generic version
of Sutent capsules, Teva held the only active DMF for sunitinib
malate reported by the FDA.
PHARMA MATTERS | MOVERS AND SHAKERS
8. SeCTiOn iv: nOTAble DeAlS
Much of the deal making activity in Q2 involved big
pharmaceuticals expanding their presence in rapidly
developing, emerging generic markets in India, Latin America,
and Japan.
AbbOTT
One of the most active deal makers in Q2 was Abbott. After
obtaining a diverse portfolio of branded generics products and
significant presence in emerging markets by acquiring Solvay
Pharmaceuticals at the beginning of the year, Abbott agreed to
pay $3.72 billion for Piramal Healthcare’s Indian formulations
business in May and announced collaboration with Zydus
Cadila. The acquisition, which also gives Abbott a production
facility at Baddi, is expected to close during the second half of
2010. According to Abbott, the deal will give them the No. 1
position in the Indian pharmaceutical market.
The collaboration agreement between Abbott and Zydus
Cadila covers the development and commercialization of
branded generics in 15 emerging markets. Initially, Abbott will
commercialize 24 products from the Zydus portfolio with an
option to commercialize more than 40 other products. The
products cover a number of therapeutic areas, including pain,
cancer, respiratory, neurological, and cardiovascular diseases.
pfizer
Pfizer, meanwhile, announced in May that it had entered into
two more collaboration agreements with Strides Arcolab
of India. Recall that in January, Pfizer expanded an earlier
arrangement with the Indian generic company, Strides
Arcolabs, for the supply of 40 off-patent products, including
mostly injectable anti-cancer treatments. One of the May
agreements covers 38 generic oncology products which Pfizer
will commercialize in the EU, Canada, Japan, Korea, Australia,
and New Zealand. The second agreement involves Pfizer
commercializing niche sterile injectables in the US
SAnOfi-AvenTiS
In the second quarter, Sanofi-Aventis announced a joint venture
with Japan’s Nichi-Iko to boost its profile in the fast-growing
generic drug market in Japan. The company’s goal is to be in
the top five generic drug producers in the Japanese market
within five years. For more information about the opportunities
and challenges foreign companies face in pursuing Japan’s
generic market, download our white paper, The Japanese
Generic Drug Market: Opportunities and Strategies for Success, at
go.thomsonreuters.com/japanese_whitepaper.
PHARMA MATTERS | MOVERS AND SHAKERS
9. glAxOSmiTHKline
GlaxoSmithKline expanded its business in Latin America by
acquiring Laboratorios Phoenix in Argentina. Phoenix has a
broad portfolio of branded generics covering therapeutic areas
including cardiovascular, gastroenterology, metabolic, and
urology. The deal also includes a manufacturing facility near
Buenos Aires.
vAleAnT
Not to be outdone by big pharma, generic companies also were
involved in significant deal-making, with Valeant, a branded
generics and specialty pharmaceutical company based in
California, standing out. The company, which agreed to merge
with Biovail of Canada in June, completed its acquisition of New
Jersey’s Aton Pharma in May, and announced an agreement
to acquire a Canadian OTC company called Vital Science Corp
in April. Also in April, Valeant announced an agreement to
acquire yet another privately held branded generics company
in Brazil. Within the last 12 months, Valeant has acquired
Bunker Industria Farmacêutica Ltda and Instituto Terapêutico
Delta Ltda in Brazil, along with Tecnofarma SA de CV and
Laboratorios Grossman SA in Mexico.
OTHer
Other major deals by generic companies in the second quarter
included the definitive agreement for Sandoz to acquire Oriel
Therapeutics, a privately-held US specialty pharmaceutical
company focused on respiratory care. This acquisition will give
Sandoz exclusive rights to a portfolio of generic candidates,
three development projects, Oriel’s FreePath drug delivery
system, and Solis multi-dose dry powder inhaler, which uses
the FreePath technology. It has been reported that FreePath
has the potential to address some of the hurdles facing
regulatory approval of generic inhaled medicines in the US
In May, Endo announced an agreement to acquire
HealthTronics, a leading US provider of urological products
and services. The deal is part of Endo’s strategy to diversify and
expand its offerings of urology products.
Orchid, an Indian generic company, is trying to buy Karalex, a
sales and marketing operation in the US The company needs an
increased US-based sales capability in order to take advantage
of its pipeline, which includes patent challenge products that
Orchid is believed to have been the first to file for, and is thus
entitled to exclusivity. Karelex was founded in 2007 by two
former executives of Par Pharmaceutical.
PHARMA MATTERS | MOVERS AND SHAKERS
10. SeCTiOn v: Opening mOveS
Based on our research of ANDA filings and Paragraph IV
challenges, we highlight some of the companies making
significant game play in the US generics industry.
ipCA lAbOrATOrieS lTD.
Ipca is a fully integrated pharmaceutical company based in
Mumbai, India, making both finished dose products and active
pharmaceutical ingredients for many international markets.
Ipca’s active pharmaceutical ingredients (API) manufacturing
facility at Ratlam has been inspected by the US FDA on a
number of occasions. The company sells numerous APIs from
that facility to the US market. Its dose facility has also been
inspected by the US FDA.
Ipca, which holds 10 active ANDAs, has so far launched most of
its products to the US market through alliances.
In 2006, Ipca entered into a strategic alliance with Ranbaxy
Pharmaceuticals Inc. (now part of Daiichi). Under this alliance,
the products were going to be marketed by Ranbaxy. Initially
the dose products were going to be manufactured by Ranbaxy
using Ipca’s active ingredients. Subsequently, both the API
and finished dose were going to be manufactured by Ipca. The
alliance covered a number of products, including atenolol,
furosemide, hydrochlorothiazide, hydroxychloroquine sulfate,
metformin HCl, and metoclopramide. The ANDA for metformin
has since been discontinued.
In 2007, Ipca entered into another strategic alliance focused
on the US market, this time with Heritage Pharmaceuticals of
New Jersey. Under the terms of the agreement, Ipca was going
to develop, register, and manufacture the products, including
propranolol, and Heritage would sell and market them in the US
inTellipHArmACeuTiCS inTernATiOnAl inC.
Intellipharmaceutics of Toronto, Canada, specializes in the
research, development, and manufacture of both novel and
generic controlled-release and targeted-release oral solid
dosage drugs.
The company is currently involved in a number of patent
challenges in the US One of the challenges was in
partnership with Par Pharmaceutical for a generic version
of the Attention Deficit Hyperactivity Disorder (ADHD) drug
Focalin XR® (dexmethylphenidate hydrochloride). In May
2010, the parties stipulated to the dismissal of the litigation.
Intellipharmaceutics’ management expects that marketing of
its generic version of Focalin XR would commence no sooner
than Q4 2012.
PHARMA MATTERS | MOVERS AND SHAKERS
11. Intellipharmaceutics’ partnership with Par Pharmaceutical
goes back several years. In November 2005, the two companies
announced an agreement for the US market to co-develop
controlled release formulations of generic drug products. In
August 2007, Par Pharmaceutical purchased a 4.2 percent
equity interest in Intellipharmaceutics and the two companies
entered into another agreement regarding the development
and launch of controlled release generic drug products,
bringing the total number of drugs under development to six.
In May 2010, Intellipharmaceutics announced that the US FDA
had accepted its filing for an ANDA for a generic version of the
antidepressant Effexor XR® (venlafaxine hydrochloride). On
June 14, 2010, the company announced it had filed an ANDA
for a generic version of Protonix® (delayed release pantoprazole
sodium). The company has since then been sued by Wyeth
LLC, a wholly owned subsidiary of Pfizer Inc., regarding
its venlafaxine application. The company also has generic
carvedilol and seven undisclosed products in its pipeline.
PHARMA MATTERS | MOVERS AND SHAKERS